MedTrace Logo

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

NCT05481151 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2025-08-13

No results posted yet for this study

Summary

A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients with PV

Conditions

Interventions

DRUG

P1101 (Ropeginterferon alfa-2b-njft)

Ropeginterferon alfa-2b-njft

DRUG

Ropeginterferon alfa-2b-njft (P1101)

Ropeginterferon alfa-2b-njft

Sponsors & Collaborators

  • PharmaEssentia

    lead INDUSTRY

Principal Investigators

  • Ole Zagrijtschuk, MD, PhD · PharmaEssentia Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-26
Primary Completion
2025-06-30
Completion
2027-07-31
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05481151 on ClinicalTrials.gov